Evidence map›Paper›PMID 37187576›Full record

ArticlePatient preference and adherence2023

Survey on the Impact of the COVID-19 Pandemic on Patients with Parkinson's Disease and Their Caregivers in Japan.

Nobutaka Hattori, Yoshiko Okada, Yayoi Kawata, Yoshihiko Furusawa, Takumi Imai, Hisako Yoshida, Mihoko Ota, Masaki Arai, Ayumi Shintani, Jovelle Fernandez

Abstract read
In one paragraph

Article in Patient preference and adherence, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Nobutaka HattoriDepartment of Neurology, Juntendo University, Tokyo, Japan.ORCID 0000-0002-2034-2556
Yoshiko OkadaJapan Parkinson Congress, Tokyo, Japan.ORCID 0000-0002-3634-2809
Yayoi KawataJapan Medical Office, Takeda Pharmaceutical Company Limited, Tokyo, Japan.
Yoshihiko FurusawaJapan Medical Office, Takeda Pharmaceutical Company Limited, Tokyo, Japan.ORCID 0000-0002-4214-6089
Takumi ImaiDepartment of Medical Statistics, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Hisako YoshidaDepartment of Medical Statistics, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Mihoko OtaJapan Medical Office, Takeda Pharmaceutical Company Limited, Tokyo, Japan.ORCID 0000-0002-0492-0192
Masaki AraiJapan Medical Office, Takeda Pharmaceutical Company Limited, Tokyo, Japan.ORCID 0000-0001-6045-378X
Ayumi ShintaniDepartment of Medical Statistics, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.ORCID 0000-0002-3323-110X
Jovelle FernandezJapan Medical Office, Takeda Pharmaceutical Company Limited, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: The coronavirus disease 2019 (COVID-19) pandemic changed the lives of patients with Parkinson's disease (PD) and their caregivers. This study aimed to investigate changes in patient behavior and PD symptoms and their effect on caregiver burden resulting from the COVID-19 pandemic in Japan. Methods: This nationwide, observational, cross-sectional survey included patients with self-reported PD and caregivers (members of the Japan Parkinson's Disease Association). The primary objective was to evaluate changes in behaviors, self-assessed PD symptoms, and caregiver burden from pre-COVID-19 (February 2020) to post-national state of emergency (August 2020 and February 2021). Results: Responses from 1883 patients and 1382 caregivers from 7610 distributed surveys were analyzed. Mean (standard deviation) age of patients and caregivers was 71.6 (8.2) and 68.5 (11.4) years, respectively; 41.6% of patients had a Hoehn and Yahr (HY) scale of 3. Patients (>40.0%) reported decreased frequency of going out. Most patients (>70.0%) reported no change in treatment visit frequency, voluntary training, or rehabilitation and nursing care insurance services. Symptoms worsened for approximately 7-30% of patients; the proportion with HY scale 4-5 increased from pre-COVID-19 (25.2%) to February 2021 (40.1%). Aggravated symptoms included bradykinesia, walking, gait speed, depressed mood, fatigue, and apathy. Caregivers' burden increased because of patients' worsened symptoms and reduced time going out. Conclusion: Control measures during infectious disease epidemics should consider that patients' symptoms may worsen; therefore, patient and caregiver support is needed to reduce burden of care.

Indexed as

caregiver burdenCOVID-19Parkinson’s diseasequestionnaire design

Identifiers

PMID37187576
PMCPMC10179078

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.